61 related articles for article (PubMed ID: 28976794)
1. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
2. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
[TBL] [Abstract][Full Text] [Related]
3. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
4. A preoperative CT-based deep learning radiomics model in predicting the stage, size, grade and necrosis score and outcome in localized clear cell renal cell carcinoma: A multicenter study.
Nie P; Liu S; Zhou R; Li X; Zhi K; Wang Y; Dai Z; Zhao L; Wang N; Zhao X; Li X; Cheng N; Wang Y; Chen C; Xu Y; Yang G
Eur J Radiol; 2023 Sep; 166():111018. PubMed ID: 37562222
[TBL] [Abstract][Full Text] [Related]
5. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma.
Hakimi AA; Mano R; Ciriello G; Gonen M; Mikkilineni N; Sfakianos JP; Kim PH; Motzer RJ; Russo P; Reuter VE; Hsieh JJ; Ostrovnaya I
J Urol; 2014 Jul; 192(1):24-9. PubMed ID: 24518768
[TBL] [Abstract][Full Text] [Related]
6. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
7. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.
Vilorio-Marqués L; Martín V; Diez-Tascón C; González-Sevilla MF; Fernández-Villa T; Honrado E; Davila-Batista V; Molina AJ
Sci Rep; 2017 Oct; 7(1):13806. PubMed ID: 29061982
[TBL] [Abstract][Full Text] [Related]
8. Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma.
Purdue MP; Rhee J; Moore L; Gao X; Sun X; Kirk E; Bencko V; Janout V; Mates D; Zaridze D; Petruzella S; Hakimi AA; Linehan WM; Chanock SJ; Brennan P; Furberg H; Troester M; Rothman N
Int J Cancer; 2021 Oct; 149(7):1448-1454. PubMed ID: 34058014
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of EZH2 in Acute Myeloid Leukemia.
Jiao W; Liu Y; Bao Y
Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
[TBL] [Abstract][Full Text] [Related]
10. Circulating Concentrations of Vitamin B6 and Kidney Cancer Prognosis: A Prospective Case-Cohort Study.
Muller DC; Johansson M; Zaridze D; Moukeria A; Janout V; Holcatova I; Navratilova M; Mates D; Midttun Ø; Ueland PM; Brennan P; Scelo G
PLoS One; 2015; 10(10):e0140677. PubMed ID: 26506437
[TBL] [Abstract][Full Text] [Related]
11. The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma.
Zhu X; He L; Zheng Z; Wang Y; Yang J; Zhang B; Wang C; Li Z
Histol Histopathol; 2024 Mar; ():18732. PubMed ID: 38567631
[TBL] [Abstract][Full Text] [Related]
12. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
13. RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability.
Wu Y; Xu Z; Chen X; Fu G; Tian J; Jin B
Cancer Med; 2023 Oct; 12(19):19889-19903. PubMed ID: 37747077
[TBL] [Abstract][Full Text] [Related]
14. The LMR-SSIGN-MAPS model predicts disease-free survival in patients with localized clear cell renal cell carcinoma.
Wen H; Zhang Y; Yang Z; Zhai Z; Han Z; Wang H; Wang M; Shi H; Chen X; Wahafu W; Guan K; Wang X
Wideochir Inne Tech Maloinwazyjne; 2023 Jun; 18(2):313-327. PubMed ID: 37680736
[TBL] [Abstract][Full Text] [Related]
15. The role of histone methylation in renal cell cancer: an update.
Hou Y; Yuan Y; Li Y; Wang L; Hu J; Liu X
Mol Biol Rep; 2023 Mar; 50(3):2735-2742. PubMed ID: 36575323
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-based prognosis signature for survival prediction of patients with clear cell renal cell carcinoma.
Chen S; Guo T; Zhang E; Wang T; Jiang G; Wu Y; Wang X; Na R; Zhang N
Heliyon; 2022 Sep; 8(9):e10578. PubMed ID: 36158103
[TBL] [Abstract][Full Text] [Related]
17. Combining expression of RNF43 and infiltration level of CD163
Zhu D; Shi X; Tian Y; Li H; Tang B; Zhang Z; Zhang Z; Zuo L
Cancer Med; 2023 Feb; 12(4):3962-3971. PubMed ID: 36097369
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning.
Acosta PH; Panwar V; Jarmale V; Christie A; Jasti J; Margulis V; Rakheja D; Cheville J; Leibovich BC; Parker A; Brugarolas J; Kapur P; Rajaram S
Cancer Res; 2022 Aug; 82(15):2792-2806. PubMed ID: 35654752
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
